Hoth Therapeutics secures a U.S. patent for exon-skipping allergy therapy. Read what this means for immunology strategy, clinical risk, and future drug development.
Hoth’s HT-001 showed 100% response in EGFR therapy toxicity trial. Learn what this means for cancer symptom relief, treatment continuity, and future trials.
Hoth Therapeutics, Inc. has filed two provisional U.S. patents for its investigational therapy HT-001, aiming to address skin toxicities caused by radiation and targeted cancer therapies. The dual filings mark a deliberate expansion into oncology-adjacent dermatology, establishing a new intellectual property footprint around treatment-induced skin damage, including adverse effects linked to menin inhibitors. This signals […]